Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centres: Results of the Daptomycin Surveillance Programme (2002-2004)

Clinical Microbiology and Infection

Volumn 12, Issue 9, 2006, Pages 844-852

  Sader, Helio S ^a,b   Streit, J M ^a   Fritsche, T R ^a   Jones, R N ^a,c  

^a JMI LABORATORIES   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial susceptibility; Daptomycin; Europe; Gram positive pathogens; Resistance; Surveillance

Indexed keywords

AMPICILLIN; CALCIUM; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; METICILLIN; OXACILLIN; STREPTOMYCIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BELGIUM; BETA HEMOLYTIC STREPTOCOCCUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; DILUTION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; EUROPE; FOOD AND DRUG ADMINISTRATION; GRAM POSITIVE BACTERIUM; GREECE; HUMAN; IRELAND; ISRAEL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; SWEDEN; SWITZERLAND; UNITED KINGDOM; UNITED STATES;

BACTERIA (MICROORGANISMS); ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 33746626047     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01550.x     Document Type: Article

References (27)

1. Tiemersma EW, Bronzwaer SL, Lyytikainen O et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg Infect Dis 2004; 10: 1627-1634.
2. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 2004; 50: 59-69.
3. Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994; 13: 50-55.
4. Mascini EM, Bonten MJ. Vancomycin-resistant enterococci: Consequences for therapy and infection control. Clin Microbiol Infect 2005; 11 (suppl 4): 43-56.
5. Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004; 39: 539-545.
6. Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus - New York. MMWR 2004; 53: 322-323.
7. Thorne GM, Adler J. Daptomycin: A novel lipopeptide antibiotic. Clin Microbiol Newslett 2002; 24: 33-39.
8. Tally FP, DeBruin MF. Development of daptomycin for gram-positive infections. J Antimicrob Chemother 2000; 46: 523-526.
9. Carpenter CF, Chambers HF. Daptomycin: Another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004; 38: 994-1000.
10. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673-1681.
11. Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide. Diagn Microbiol Infect Dis 2004; 50: 201-204.
12. Cunha BA, Hamid N, Kessler H, Parchuri S. Daptomycin cure after cefazolin treatment failure of methicillin-sensitive Staphylococcus aureus (MSSA) tricuspid valve acute bacterial endocarditis from a peripherally inserted central catheter (PICC) line. Heart Lung 2005; 34: 442-447.
13. Finney MS, Crank CW, Segreti J. Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections. Curr Med Res Opin 2005; 21: 1923-1926.
14. Rouse MS, Piper KE, Jacobson M, Jacofsky DJ, Steckelberg JM, Patel R. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother 2006; 57: 301-305.
15. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: In vitro modeling and clinical impact. J Infect Dis 2005; 191: 2149-2152.
16. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th edn. Approved standard M7-A7. Wayne, PA: CLSI, 2006.
17. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 16th informational supplement. M100-S16. Wayne, PA: CLSI, 2006.
18. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee. EUCAST Technical Note on daptomycin. Clin Microbiol Infect 2006; 12: 599-601.
19. Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit - a European and North American surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004; 3: 14.
20. Johnson AP, Pearson A, Duckworth G. Surveillance and epidemiology of MRSA bacteraemia in the UK. J Antimicrob Chemother 2005; 56: 455-462.
21. Muto CA, Jernigan JA, Ostrowsky BE et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003; 24: 362-386.
22. Hsueh PR, Chen WH, Teng LJ, Luh KT. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents 1991; 26: 43-49.
23. Haroche J, Morvan A, Davi M, Allignet J, Bimet F, El Solh N. Clonal diversity among streptogramin A-resistant Staphylococcus aureus isolates collected in French hospitals. J Clin Microbiol 2003; 41: 586-591.
24. Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial activity of daptomycin tested against gram-positive strains collected from European medical centers in 2005: Results of the Daptomycin Surveillance Programme. Clin Microbiol Infect 2006; 12 (suppl 4): P1261.
25. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 2538-2544.
26. Fluit AC, Schmitz FJ, Verhoef J, Milatovic D. In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants. Antimicrob Agents Chemother 2004; 48: 1007-1011.
27. Eliopoulos GM. Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci. Eur J Clin Microbiol Infect Dis 2005; 24: 826-831.